David Kandzari, MD
Interventional Cardiology · Atlanta, GANPI 1871677930
Payments from drug & device makers
Across 1,032 payments — averaging $3591.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2.8M
- Corindus Inc.$513K
- Arrow International, Inc.$118K
- Cardiovascular Systems Inc.$84K
- Biotronik Inc.$73K
- Abbott$48K
- plus $100K from 25 others
Across 28 payments — averaging $4061.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$85K
- Biotronik Inc.$25K
- Balt USA, LLC$4K
What the payments were for
- Consulting fees$136,97814%
- Speaking & faculty fees$144,91915%
- Grants$8780%
- Travel & lodging$171,49817%
- Food & beverage$14,5371%
- Gifts$1060%
- Ownership interest$513,00052%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 534 | $2,770,514 |
| Corindus Inc. | 1 | $513,000 |
| Arrow International, Inc. | 17 | $118,253 |
| Cardiovascular Systems Inc. | 58 | $83,808 |
| Biotronik Inc. | 251 | $73,144 |
| Abbott | 45 | $47,552 |
| Boston Scientific | 42 | $35,356 |
| Ablative Solutions, Inc. | 19 | $34,603 |
| Amplitude Vascular Systems, Inc. | 1 | $10,725 |
| Cordis US CORP. | 8 | $6,963 |
| Teleflex LLC | 10 | $4,602 |
| Magenta Medical Inc | 2 | $3,770 |
| Terumo Medical Corporation | 4 | $1,700 |
| Arrow Interventional, Inc. | 1 | $1,000 |
| Siemens Medical Solutions USA, Inc. | 2 | $284 |
| Shockwave Medical, Inc | 8 | $277 |
| Cagent Vascular Inc | 1 | $191 |
| Johnson & Johnson | 9 | $162 |
| Edwards Lifesciences | 1 | $132 |
| Abiomed | 1 | $106 |
| Merck | 1 | $100 |
| Philips North America LLC | 2 | $98 |
| Acist Medical Systems, Inc. | 1 | $81 |
| Pfizer | 3 | $70 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $15 |
| Asahi Intecc USA, Inc. | 1 | $15 |
| Vantis Vascular, Inc. | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$72,061
- Diamondback Coronary$64,013
- SYMPLICITY G3$26,266
- Xience V coronary stent system$21,671
- Coronary Orbital Atherectomy System$17,229
- Diamondback Peripheral$10,157
- RESOLUTE ONYX$9,528
- Integrity$7,884
- XACT$3,920
- SELUTION SLR PTA$3,382
- TURNPIKE$3,283
- PK Papyrus$1,700
- cardio$1,551
- GENERAL VASCULAR ACCESS$1,358
- Orsiro Mission$1,325
- GUIDELINER$1,024
- GUIDELINER V3 CATHETER$1,000
- SELUTION SLRPTCA$607
- Optitorque$350
- AVVIGO Guidance System$305
How this compares
$3,706,644 in reported general payments places this provider in the 95th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 84 | $84,389 |
| BrilintaTicagrelor | 12 | $12,787 |
| NexletolBempedoic Acid | 12 | $8,332 |
| Rosuvastatin Calcium | 398 | $5,858 |
| ClopidogrelClopidogrel Bisulfate | 388 | $4,647 |
| Nifedipine ErNifedipine | 107 | $4,361 |
| Ranolazine ErRanolazine | 49 | $4,304 |
| Ezetimibe | 193 | $3,903 |
| Prasugrel Hcl | 52 | $2,792 |
| Metoprolol Succinate | 176 | $1,965 |
| Atorvastatin Calcium | 163 | $1,676 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 69 | $1,187 |
| Losartan Potassium | 136 | $897 |
| Carvedilol | 44 | $516 |
| Hydralazine Hcl | 31 | $514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $70 | $84,38984 claims |
| Esperion Therapeutics, Inc.Nexletol | $22 | $8,33212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Atlanta
- Pradeep YadavAtlanta$3.5M
- Vasilis BabaliarosAtlanta$2.7M
- William NicholsonAtlanta$2M
- Chandanreddy DevireddyAtlanta$1.9M
- Adam GreenbaumAtlanta$1.8M
- Vivek RajagopalAtlanta$1.3M
- Christopher MeduriAtlanta$1.1M
- Wissam JaberAtlanta$981K
- George HanzelAtlanta$750K
- Andrew KleinAtlanta$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.